Stay updated on LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial

Sign up to get notified when there's something new on the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Removed the footer notice about government funding and operating status. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-17T17:27:31.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    New entries have been added to the Record History, showing updated study status and recruitment information.
    Difference
    0.1%
    Check dated 2025-11-03T12:26:49.000Z thumbnail image
  4. Check
    45 days ago
    Change Detected
    Summary
    - Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.
    Difference
    11%
    Check dated 2025-10-05T17:25:33.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no substantive content changes detected.
    Difference
    0.3%
    Check dated 2025-09-28T10:38:09.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.6%
    Check dated 2025-09-14T00:21:59.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.7%
    Check dated 2025-09-06T21:18:34.000Z thumbnail image

Stay in the know with updates to LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page.